相关临床试验
22
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1980
已完成
8
36.4%
Enrolling By Invitation
2
9.1%
尚未招募
2
9.1%
招募中
7
31.8%
Unknown
3
13.6%
暂无批准数据
- Massive Bio and BeeKeeperAI have launched a federated confidential computing platform to expand oncology clinical trial access across underserved communities in Atlanta using AI-powered patient pre-screening. - The collaboration leverages EscrowAI's privacy-enhancing technology to enable AI models to operate directly on sensitive cancer data within healthcare providers' environments without exposing patient information. - The initiative addresses the critical gap in clinical trial participation among underrepresented populations by allowing AI to travel to the data rather than requiring sensitive patient data to be transferred externally. - The platform maintains strict HIPAA compliance while generating pre-screening reports that help providers quickly identify potential trial candidates for precision oncology studies.
- Freenome's PREEMPT CRC study, involving 48,995 participants, represents the largest prospective study of a blood-based colorectal cancer screening test and met all primary efficacy endpoints. - The test demonstrated 100% sensitivity for colorectal cancer and 94.8% specificity for advanced colorectal neoplasia in adults aged 45-49, a population with only 20% screening compliance. - FDA premarket approval submission is underway with completion anticipated by mid-2025, potentially offering a non-invasive alternative to address screening barriers affecting over 40% of eligible U.S. adults.
- Sanofi is investing $18 million over 10 years in three Historically Black Medical Schools (HBMCs) to establish Centers of Excellence for clinical study diversity. - The initiative aims to address the underrepresentation of Black individuals in clinical research, ensuring treatments are effective and safe for Black patients. - Funding will support hiring clinical research staff, upgrading infrastructure, and developing customized training programs at Howard, Meharry, and Morehouse. - The investment aligns with the FDA mandate for diversity in clinical trials, promoting equitable healthcare interventions and trust within Black communities.
